32708
document
A double-blind , randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus . The efficacy and safety of tesaglitazar ( 0.5 and 1 mg ) and pioglitazone ( 15 , 30 and 45 mg ) were compared in a 24-week , randomised , double-blind study in 1,707 patients with type 2 diabetes mellitus . Tesaglitazar 1 mg was non-inferior to pioglitazone 45 mg for change from baseline in glycosylated haemoglobin ( HbA1C ) at 24 weeks ( difference : -0.056 [ 95 % confidence intervals -0.161 , 0.049 ] , pNI < 0.001 for non-inferiority hypothesis ) . Tesaglitazar 1 mg improved triglyceride ( TG ) , high-density lipoprotein cholesterol ( HDL-C ) and non-HDL-C levels compared with all pioglitazone doses at 24 weeks ( p < 0.001 ) . Low-density lipoprotein cholesterol ( LDL-C ) was lower with tesaglitazar for all pioglitazone comparisons ( p < 0.05 ) , except for tesaglitazar 0.5 mg versus pioglitazone 15 mg. Tesaglitazar 1 mg decreased LDL particle number , when compared with all pioglitazone doses ( p < 0.01 ) . Both agents increased body weight and peripheral oedema in a dose-dependent manner , but only tesaglitazar increased serum creatinine . In summary , tesaglitazar provided similar glycaemic control to pioglitazone , was associated with significant improvement in lipid and lipoprotein variables , and increased serum creatinine in a dose-dependent manner .
32709
Intervention_Pharmacological
tesaglitazar
32710
Intervention_Pharmacological
pioglitazone
32711
Intervention_Pharmacological
tesaglitazar
32712
Intervention_Pharmacological
pioglitazone
32713
Intervention_Pharmacological
Tesaglitazar
32714
Intervention_Pharmacological
pioglitazone
32715
Intervention_Pharmacological
Tesaglitazar
32716
Intervention_Pharmacological
tesaglitazar
32717
Intervention_Pharmacological
pioglitazone
32718
Intervention_Pharmacological
tesaglitazar
32719
Intervention_Pharmacological
pioglitazone
32720
Intervention_Pharmacological
Tesaglitazar
32721
Intervention_Pharmacological
pioglitazone
32722
Intervention_Pharmacological
tesaglitazar
32723
Intervention_Pharmacological
tesaglitazar
32724
Intervention_Pharmacological
pioglitazone
32725
Outcome_Physical
triglyceride ( TG ) , high-density lipoprotein cholesterol ( HDL-C ) and non-HDL-C levels
32726
Outcome_Physical
Low-density lipoprotein cholesterol ( LDL-C )
32727
Outcome_Physical
LDL particle number
32728
Outcome_Physical
body weight and peripheral oedema
32729
Outcome_Physical
serum creatinine .
32730
Outcome_Physical
glycaemic control
32731
Outcome_Physical
lipid and lipoprotein variables
32732
Participant_Condition
type 2 diabetes mellitus
32733
Participant_Sample-size
1,707
32734
Participant_Condition
type 2 diabetes mellitus